Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

British journal of cancer

Volumn 110, Issue 8, 2014, Pages 1968-1976

  Tural, D ^a   Serdengecti, S ^a   Demirelli, F ^a   Ozturk T ^a   Ilvan, S ^a   Turna, H ^a   Ozguroglu M ^a   Buyukunal E ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ELAFIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PI3 PROTEIN, HUMAN; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; TRASTUZUMAB; VAV PROTEIN; VAV1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ELAFIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-VAV; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2;

EID: 84901944005     PISSN: None     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.72     Document Type: Article

References (0)